Pre-registration is now closed. We welcome you to register on-site at the Sheraton Grand Chicago (301 E North Water Street), Chicago Ballroom VI (Ballroom Level) at 6:30 PM. Remember to bring your ASCO Annual badge to expedite your registration.
Welcome and Overview
Selecting First-line Therapy in the Setting of EGFR-Mutated NSCLC (Case Discussion)
Selecting Second-line Therapy and Beyond in the Setting of EGFR-Mutated NSCLC (Case Discussion)
Future Directions in Treatment Strategies for EGFR-Mutated NSCLC
Conclusions and Final Question and Answer Session
Date / Time
Shirish M. Gadgeel, MD
Mary Lou Kennedy Research Professor in Thoracic Oncology
Co-Leader, Thoracic Oncology Research Program
Associate Director, Cancer Care at Networking and Affiliation Centers
Division of Hematology/Oncology
Department of Internal Medicine
University of Michigan
Ann Arbor, Michigan
Heather Wakelee, MD
Professor of Medicine, Oncology
Department of Medicine/Oncology
Stanford University/Stanford Cancer Institute
Helena Yu, MD
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
The goal of this activity is to improve participants’ knowledge of and competence in applying EGFR inhibitors in the treatment of patients with EGFR-mutated non-small-cell lung cancer.
This program is intended for physicians, oncology nurses, pharmacists, and other healthcare providers who care for patients with non-small-cell lung cancer.
- Apply expert recommendations for frontline therapy for advanced EGFR-mutated NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors
- Compare the efficacy and safety of first-generation EGFR TKIs with later-generation EGFR TKIs
- Examine current recommendations for molecular testing and the roles for liquid biopsies in guiding the use of EGFR TKI therapy
- Plan optimal sequencing of EGFR TKIs after considering the available evidence and expert recommendations
- Evaluate current and evolving treatment approaches to address acquired resistance and progression in advanced EGFR-mutated NSCLC
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-18-300-L01-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.